The PPARs: From Orphan Receptors to Drug Discovery
The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTThe PPARs: From Orphan Receptors to Drug Discovery†Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach, and Brad R. HenkeView Author Information Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709 Cite this: J. Med. Chem. 2000, 43, 4, 527–550Publication Date (Web):February 24, 2000Publication History Received8 November 1999Published online24 February 2000Published inissue 1 February 2000https://pubs.acs.org/doi/10.1021/jm990554ghttps://doi.org/10.1021/jm990554greview-articleACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views6740Altmetric-Citations1452LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Agonists,Ligands,Lipids,Receptors,Rodent models Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is an extremely selective PPARα agonist (subtype selectivity > 5000-fold for PPARγ and > 11,000-fold for PPARδ, respectively) [49, 50].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
In the citing paper
“The PPARα activation by pemafibrate was > 2500 times stronger than fenofibric acid, the active form of fenofibrate.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
Citations
Cites
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Self-citationA Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Research works printed but not linked: 124
- Lichtenstein A. H., 1998, Nutr. Rev., 56, S28
- Harris M. I., 1998, Diabetes Care, 21, 524
- Howard B. V., 1995, Int. Congr. Ser.
- Barzilai N., 1999, J. Gerontol., Ser. A, 54, B96
- Lichtenstein A. H., 1999, Nutr. Rev., 57, 14
- Jump D. B., 1999, Annu. Rev. Nutr., 19, 90
- Mangelsdorf D. J., 1995, Cell, 83, 850
- A, 1999, Cell, 97, 163
- Xu H. E., 1999, Mol. Cell, 3, 403
- Hu E., 1996, Science, 274, 2103
- Zhang B., 1996, J. Biol. Chem., 271, 31774
- Adams M., 1997, J. Biol. Chem., 272, 5132
- Camp H. S., 1999, Endocrinology, 140, 397
- Juge-Aubry C. E., 1999, J. Biol. Chem., 274, 10510
- McDonnell D. P., 1993, Bio/Technology, 11, 1261
- Lehmann J. M., 1995, J. Biol. Chem., 270, 12956
- Xu L., 1999, Curr. Opin. Genet. Dev., 9, 147
- Zhu Y., 1996, Gene Expression, 6, 195
- Dowell P., 1997, J. Biol. Chem., 272, 33443
- Zhu Y., 1997, J. Biol. Chem., 272, 25506
- Yuan C.-X., 1998, Proc. Natl. Acad. Sci. U.S.A., 95, 7944
- Treuter E., 1998, Mol. Endocrinol., 12, 881, 10.1210/mend.12.6.0123 · doi:10.1210/mend.12.6.0123 · Paper page
- Krey G., 1997, Mol. Endocrinol., 11, 791, 10.1210/mend.11.6.0007 · DOI · Paper page
- Zhou G., 1998, Mol. Endocrinol., 12, 1604, 10.1210/mend.12.10.0176 · doi:10.1210/mend.12.10.0176 · Paper page
- Berger J., 1996, Endocrinology, 137, 4195
- Young P. W., 1998, J. Pharmacol. Exp. Ther., 284, 759
- Bell A. R., 1998, Biochem. J., 332, 693
- Heuvel J. P. V, 1999, Toxicol. Sci., 47, 8
- Palmer C. N. A., 1998, Mol. Pharmacol., 53, 22
- Gervois P., 1999, Mol. Endocrinol., 13, 1549
- Gaw A., 1994, Handb. Exp. Pharmacol., 109, 348
- Brown P. J., 1997, Synthesis, 778, 782
- Brown P. J., 1999, J. Med. Chem., 42, 3788
- Forman B. M., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 4317
- Yu K., 1995, J. Biol. Chem., 270, 23983
- Palmer C. N. A., 1994, J. Biol. Chem., 269, 18089
- Lee S. S.-T., 1995, Mol. Cell. Biol., 15, 3022
- Peters J. M., 1997, J. Biol. Chem., 272, 27312
- Gaw A., 1999, Lipoproteins Health Dis., 1145, 1160
- Ross S. D., 1999, Arch. Intern. Med., 159, 1802
- Oliver M. F., 1984, Lancet, 2, 604
- Rutolo G., 1998, J. Am. Coll. Cardiol., 32, 1656
- Libby P., 1999, Mol. Basis Cardiovasc. Dis., 349, 366
- Spencer N. F. L., 1997, Int. Immunol., 9, 1588
- Delerive P., 1999, J. Biol. Chem., 45, 32054
- Vazquez M., 1995, Br. J. Pharmacol., 116, 2075
- Jacobsson A., 1985, J. Biol. Chem., 260, 16254
- Krook A., 1998, Diabetes, 47, 1531
- Ruyter B., 1997, Biochim. Biophys. Acta, 1348, 338
- Zhu Y., 1993, J. Biol. Chem., 268, 26820
- Greene M. E., 1995, Gene Expression, 4, 299
- Chawla A., 1994, Endocrinology, 135, 800, 10.1210/endo.135.2.8033830 · doi:10.1210/endo.135.2.8033830 · Paper page
- Saladin R., 1999, Cell Growth Differ., 10, 48
- Martin G., 1997, J. Biol. Chem., 272, 28217
- Hofmann C., 1994, Endocrinology, 134, 270, 10.1210/endo.134.1.8275942 · DOI · Paper page
- Tai T.-A. C., 1996, J. Biol. Chem., 271, 29914
- Kelly L. J., 1998, Endocrinology, 139, 4927
- Hulin B., 1996, Curr. Pharm. Des., 2, 102
- Kletzien R. F., 1992, Mol. Pharmacol., 41, 398
- Ibrahimi A., 1994, Mol. Pharmacol., 46, 1076
- Harris P. K. W., 1994, Mol. Pharmacol., 45, 445
- Willson T. M., 1996, J. Med. Chem., 39, 668
- Ide T., 1998, Diabetes Front, 9, 346
- Shinkai H., 1998, J. Med. Chem., 41, 1933
- Reginato M. J., 1998, J. Biol. Chem., 273, 32684
- Reddy K. A., 1999, J. Med. Chem., 42, 3278
- Sohda T., 1984, Chem. Pharm. Bull., 32, 4465
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2126
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2130
- Henke B. R., 1998, Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem
- Collins J. L., 1998, Structure−activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem
- Cobb J. E., 1998, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure−activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5069
- Lehmann J. M., 1997, J. Biol. Chem., 272, 3410
- Verrando P., 1981, Biochim. Biophys. Acta, 663, 265
- Negishi M., 1995, J. Lipid Mediators Cell Signalling, 12, 448
- Narumiya S., 1991, Dev. Oncol., 67, 448
- Ikeda H., 1990, Arzneim.-Forsch., 40, 162
- Horikoshi H., 1994, Annu. Rep. Sankyo Res. Lab., 46, 57
- Prigeon R. L., 1998, J. Clin. Endocrinol. Metab., 83, 823
- Fonseca V. A., 1998, J. Clin. Endocrinol. Metab., 83, 3176
- Spencer C. M., 1997, Drugs, 54, 101
- Kumar S., 1996, Diabetologia, 39, 709
- Gimble J. M., 1996, Mol. Pharmacol., 50, 1094
- Jones S. A., 2000, Mol. Endocrinol., 14, 39, 10.1210/mend.14.1.0409 · doi:10.1210/mend.14.1.0409 · Paper page
- Blumberg B., 1998, Genes Dev., 12, 3205
- Ramachandran V., 1999, Drug Metab. Dispos., 27, 1199
- Yamazaki H., 1999, Drug Metab. Dispos., 27, 1266
- Pumford N. R., 1997, Annu. Rev. Pharmacol. Toxicol., 37, 117
- Miller V. A., 1997, J. Clin. Oncol., 15, 795
- Rizvi N. A., 1999, Clin. Cancer Res., 5, 1664
- Vidal-Puig A. J., 1997, J. Clin. Invest., 99, 2422
- Park K. S., 1997, Diabetes, 46, 1234
- Wu Z., 1998, J. Clin. Invest., 101, 32
- Sreenan S., 1999, Am. J. Physiol., 276, E1129
- Miles P. D. G., 1997, Diabetes, 46, 1683
- Yen C.-J., 1997, Biochem. Biophys. Res. Commun., 241, 274
- Deeb S. S., 1998, Nat. Genet., 20, 287
- Valve R., 1999, J. Clin. Endocrinol. Metab., 84, 3712
- Mori Y., 1998, Biochem. Biophys. Res. Commun., 251, 198
- Ek J., 1999, Diabetologia, 42, 895
- Hamann A., 1999, Eur. J. Endocrinol., 141, 92
- Girard J, 1997, Diabetes Metab., 23, 24
- McKeigue P., 1997, Handb. Hypertens., 17, 934
- Dubey R. K., 1993, Am. J. Physiol., 265, R732
- Zhang H. Y., 1994, Hypertension, 24, 110
- Morikang E., 1997, Am. J. Hypertens., 10, 446
- Law R. E., 1996, J. Clin. Invest., 98, 1905
- Kotchen T. A., 1996, Am. J. Physiol., 270, R666
- Zhang F., 1994, Hypertension, 24, 175
- Su C. G., 1999, J. Clin. Invest., 104, 389
- Ehrmann D. A., 1997, J. Clin. Endocrinol. Metab., 82, 2116
- Minamikawa J., 1998, J. Clin. Endocrinol. Metab., 83, 1820
- Suh N., 1999, Cancer Res., 59, 5673
- Lefebvre A.-M., 1998, Nat. Med., 4, 1057
- Schmidt A., 1992, Mol. Endocrinol., 6, 1641
- Amri E.-Z., 1995, J. Biol. Chem., 270, 2371
- Brooks C. D. W., 1996, J. Med. Chem., 39, 2654
- Brun R. P., 1996, Genes Dev., 10, 984
- Lim H., 1999, Genes Dev., 13, 1574
- He T.-C., 1999, Cell, 99, 345
- Cobb J., 1998, Annu. Rep. Med. Chem., 33, 222
- Sliskovic D. R., 1999, Annu. Rep. Med. Chem., 34, 110
- Belch J. J. F., 1998, Proc. Nutr. Soc., 57, 569
- Woutersen R. A., 1999, Mutat. Res., 443, 127
Cited by
Items 301–400 of 1,003
Vitale, S. G., Laganà, A. S., Nigro, A., Rosa, V. L. L., Rossetti, P., Rapisarda, A. M. C., Vignera, S. L., Condorelli, R. A., Corrado, F., Buscema, M., et al. (2016) · PPAR Research · doi:10.1155/2016/6517313 · Cited by 112
“The biological effects of PPARs depend on their different ligand and the presence of several proteins that operate as coactivators or corepressors and whose presence may alter the expression of genes [6].”
García‐Bueno, B., Madrigal, J. L. M., Lizasoaín, I., Moro, M. Á., Lorenzo, P. L., & Leza, J. C. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.007 · Cited by 117
Yamazaki, K., Kuromitsu, J., & Tanaka, I. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6319 · Cited by 108
Theoretical Study of the Electrocyclic Ring Closure of Hydroxypentadienyl Cations
Faza, O. N., López, C. S., Álvarez, R., & de Lera, Á. R. (2004) · Chemistry - A European Journal · doi:10.1002/chem.200400037 · Cited by 121
Varley, C. L., Stahlschmidt, J., Smith, B. A., Stower, M. J., & Southgate, J. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63737-6 · Cited by 107
Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors
Berger, J., & Wagner, J. A. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150260007381 · Cited by 108
“28,29 Farglitazar is a very potent non-TZD PPAR g -selective agonist that was recently shown to have antidiabetic as well as lipid-al-tering efficacy in humans.”
Blanquart, C., Mansouri, R., Paumelle, R., Fruchart, J.-C., Staels, B., & Glineur, C. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0327 · Cited by 101
Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity
Proulx, K., Cota, D., Castañeda, T. R., Tschöp, M. H., D'Alessio, D. A., Tso, P., Woods, S. C., & Seeley, R. J. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00029.2005 · Cited by 103
“For instance, the PPAR- ligands Wy-14643 and the fibrate drugs clofibrate, fenofibrate, and bezafibrate are all hypolipemic agents that reduce weight gain in rodent models (40).”
BackgroundMallbris, L., O'Brien, K. P., Hulthén, A., Sandstedt, B., Cowland, J. B., Borregaard, N., & Ståhle‐Bäckdahl, M. (2002) · Experimental Dermatology · doi:10.1034/j.1600-0625.2002.110611.x · Cited by 105
“Proliferator-activated receptor isoforms are a family of transcription factors that are members of the nuclear hormone receptor superfamily (21) forming heterodimers with members of the retinoid X receptor family.”
BackgroundMae, T., Kitahara, M., Nishiyama, T., Tsukagawa, M., Konishi, E., Kishida, H., Kuroda, M., Mimaki, Y., Sashida, Y., Takahashi, K., et al. (2003) · Journal of Nutrition · doi:10.1093/jn/133.11.3369 · Cited by 111
Jiang, G., Dallas-Yang, Q., Li, Z., Szalkowski, D., Liu, F., Shen, X., Wu, M., Zhou, G., Doebber, T., Berger, J., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2412 · Cited by 109
A Review of Rosiglitazone in Type 2 Diabetes Mellitus
Werner, A. L., & Travaglini, M. T. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.13.1082.34615 · Cited by 106
“They both bind selectively to PPAR-g and improve sensitivity to insulin in muscle and adipose tissue.(17) However, differences in pharmacokinetics exist.”
BackgroundGebhardt, R., & Hovhannisyan, A. (2010) · Developmental Dynamics · doi:10.1002/dvdy.22041 · Cited by 102
Role of Peroxisome Proliferator‐Activated Receptors in Inflammation Control
Youssef, J., & Badr, M. (2004) · BioMed Research International · doi:10.1155/s1110724304308065 · Cited by 103
“This finding is in support of the hypothesis stipulating that prostacyclin and/or its metabolite(s) regulate embryo implantation by activating PPAR δ [4, 46].”
BackgroundResultInfluentialChinetti, G., Fruchart, J.-C., & Staels, B. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200310000-00006 · Cited by 103
Dietary modulation of peroxisome proliferator-activated receptor gamma
Marion‐Letellier, R., Déchelotte, P., Iacucci, M., & Ghosh, S. K. (2008) · Gut · doi:10.1136/gut.2008.162859 · Cited by 110
“transcription-activation function motifs (AF-1 and AF-2).(4) The secondary structure of the”
BackgroundNuclear receptor signaling in macrophages
Valledor, A. F., & Ricote, M. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.10.016 · Cited by 117
Ribet, C., Montastier, E., Valle, C., Bezaire, V., Mazzucotelli, A., Mairal, A., Viguerie, N., & Langin, D. (2010) · Endocrinology · doi:10.1210/en.2009-0726 · Cited by 95
“between the mouse and human nuclear receptor (18), and”
Background15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells
Clay, C. E., Monjazeb, A., Thorburn, J., Chilton, F. H., & High, K. P. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200224-jlr200 · Cited by 103
Reddy, K. J., Singh, M., Bangit, J. R., & Batsell, R. R. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e328333645a · Cited by 113
Yin, Y., Russell, R. G., Dettin, L. E., Bai, R., Wei, Z.-L., Kozikowski, A. P., Kopleovich, L., & Glazer, R. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3990 · Cited by 101
“After the last dose of DMBA, mice were maintained on either a control diet or diets containing bioequivalent concentrations of either GW7845 or GW501516, based on their respective receptor affinities (35, 36), and the dose of GW7845 used previously (22).”
MethodApplication of the Dakin−West Reaction for the Synthesis of Oxazole-Containing Dual PPARα/γ Agonists
Godfrey, A. G., Brooks, D. A., Hay, L. A., Peters, M., McCarthy, J. R., & Mitchell, D. N. (2003) · The Journal of Organic Chemistry · doi:10.1021/jo026655v · Cited by 113
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 121
Activation of PPARγ increases PTEN expression in pancreatic cancer cells
Farrow, B. J., & Evers, B. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02983-2 · Cited by 107
Combs, C. K., Bates, P., Karlo, J. C., & Landreth, G. E. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00052-3 · Cited by 108
Human genomics and obesity: finding appropriate drug targets
Ravussin, É., & Bouchard, C. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00811-6 · Cited by 118
Shi, G. Q., Dropinski, J. F., Zhang, Y., Santini, C., Sahoo, S. P., Berger, J. P., MacNaul, K. L., Zhou, G., Agrawal, A. K., Alvaro, R. F., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050373g · Cited by 101
Ravnskjær, K., Frigerio, F., Boergesen, M., Nielsen, T., Maechler, P., & Mandrup, S. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m001123 · Cited by 110
Masubuchi, Y., Kano, S., & Horie, T. (2006) · Toxicology · doi:10.1016/j.tox.2006.02.017 · Cited by 100
Fenofibrate for patients with asymptomatic primary biliary cirrhosis
Dohmen, K., Mizuta, T., Nakamuta, M., Shimohashi, N., Ishibashi, H., & Yamamoto, K. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i6.894 · Cited by 99
Grommes, C., Landreth, G. E., Sastre, M., Beck, M., Feinstein, D. L., Jacobs, A. H., Schlegel, U. S., & Heneka, M. T. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022194 · Cited by 99
“PPARs form heterodimers with the retinoic acid receptor and exhibit ligand-induced transcriptional regulatory activity through sequence-specific PPAR-responsive elements in their target genes (Willson et al., 2000).”
BackgroundLee, W.-S., & Kim, J. (2015) · PPAR Research · doi:10.1155/2015/271983 · Cited by 91
“potential to directly improve insulin sensitization via PPARγ activation [10, 15].”
Cuzzocrea, S., Paola, R. D., Mazzon, E., Genovese, T., Muià, C., Centorrino, T., & Caputi, A. P. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700185 · Cited by 98
“22 and there is a good correlation between the potency of the TZDs as PPAR- γ agonists in vitro and their efficacy at lowering glucose levels in vivo”
BackgroundPolyunsaturated Fatty Acid Biosynthesis and Metabolism in Fish
Monroig, Ó., Tocher, D. R., & Castro, L. F. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811230-4.00003-x · Cited by 140
Tenenbaum, A., Fisman, E. Z., & Motro, M. (2003) · Cardiovascular Diabetology · doi:10.1186/1475-2840-2-4 · Cited by 112
Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators
Han, S. H., Quon, M. J., & Koh, K. K. (2005) · Hypertension · doi:10.1161/01.hyp.0000187900.36455.4c · Cited by 98
Shan, W., Palkar, P. S., Murray, I. A., McDevitt, E. I., Kennett, M. J., Kang, B. H., Isom, H. C., Perdew, G. H., Gonzalez, F. J., & Peters, J. M. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn142 · Cited by 97
“In response to ligand activation, PPARs heterodimerize with the retinoid X receptor a leading to the disassociation of corepressors, recruitment of coactivators, binding to peroxisome proliferator response elements in target genes, and an increase in transcription (Berger and Moller, 2002; Willson et al., 2000).”
BackgroundBlednov, Y. A., Benavidez, J. M., Black, M., Ferguson, L. B., Schoenhard, G. L., Goate, A. M., Edenberg, H. J., Wetherill, L., Hesselbrock, V., Foroud, T., et al. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12610 · Cited by 96
“The brain levels attained are likely high enough to activate PPARa but not other PPARs (Willson et al., 2000).”
InfluentialFenofibrate inhibits angiogenesis in vitro and in vivo
Pille, J., Varet, J., Vincent, L., Mirshahi, P., Legrand, E., Opolon, P., Mishal, Z., Soria, J., Li, H., & Soria, C. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-2322-6 · Cited by 101
Cuzzocrea, S., Pisano, B., Dugo, L., Ianaro, A., Patel, N. S. A., Paola, R. D., Genovese, T., Chatterjee, P. K., Rosa, M. D., Caputi, A. P., et al. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705419 · Cited by 97
“…rosiglitazone is the most potent and selective PPAR-g agonist (Lehmann et al., 1997; Young et al., 1998; Murphy & Holder, 2000), and there is a good correlation between the potency of the TZDs as PPAR-g agonists in vitro and their efficacy at lowering glucose levels in vivo (Willson et al., 2000).”
BackgroundTreatment of insulin resistance in diabetes mellitus
Lebovitz, H. E., & Banerji, M. A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.051 · Cited by 102
Siragusa, L., Cross, S., Baroni, M., Goracci, L., & Cruciani, G. (2015) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24753 · Cited by 91
Degenhardt, T., Saramäki, A., Malinen, M., Rieck, M., Vaïsänen, S., Huotari, A., Herzig, K., Müller, R., & Carlberg, C. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.091 · Cited by 105
Kuroda, M., Mimaki, Y., Sashida, Y., Mae, T., Kishida, H., Nishiyama, T., Tsukagawa, M., Konishi, E., Takahashi, K., Kawada, T., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.052 · Cited by 95
Schmidt, S., Moric, E., Schmidt, M., Sastre, M., Feinstein, D. L., & Heneka, M. T. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0803402 · Cited by 96
“[7], reduces inflammatory gene expression and protects neurons from immunostimulated cell death [8–11].”
BackgroundTenenbaum, A., Fisman, E. Z., Boyko, V., Benderly, M., Tanne, D., Haim, M., Matas, Z., Motro, M., & Behar, S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.737 · Cited by 95
“Therefore, it has the potential to directly improve insulin sensitization via PPAR- activation.(30) To the best of our knowledge, the present study is the first large-scale report regarding the long-term effect of bezafibrate on IR.”
BackgroundShan, W., Nicol, C. J., Ito, S., Bility, M. T., Kennett, M. J., Ward, J. M., Gonzalez, F. J., & Peters, J. M. (2008) · Hepatology · doi:10.1002/hep.21925 · Cited by 93
Majdalawieh, A., & Ro, H.-S. (2010) · Nuclear Receptor Signaling · doi:10.1621/nrs.08004 · Cited by 90
“, L-165041) are potent synthetic agonists for PPARα [Willson et al., 2000], PPARγ [Berger et al.”
BackgroundNugent, C., Prins, J. B., Whitehead, J. P., Savage, D., Wentworth, J. M., Chatterjee, V. K., & O’Rahilly, S. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.10.0715 · Cited by 92
“Thus, TZDs have effects on suppression of the adipocytederived signaling molecules, TNF and leptin, and on FFA partitioning between adipose and muscle tissues ( 29 , 30), all of which may secondarily improve whole organism insulin sensitivity.”
BackgroundBoyault, S., Simonin, M.-A., Bianchi, A., Compe, E., Liagre, B., Mainard, D., Bécuwe, P., Dauça, M., Netter, P., Terlain, B., et al. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02614-x · Cited by 94
The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12448 · Cited by 95
Matin, A., Gavande, N. S., Kim, M. S., Yang, N. X., Salam, N. K., Hanrahan, J. R., Roubin, R. H., & Hibbs, D. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900964r · Cited by 93
Thangavel, N., Al Bratty, M., Akhtar Javed, S., Ahsan, W., & Alhazmi, H. A. (2017) · International Journal of Medicinal Chemistry · doi:10.1155/2017/1069718 · Cited by 87
“Glitazones have been reported to adversely affect the bodyweight [8] and can cause injury to the liver [9, 10].”
BackgroundDigging deep into the pockets of orphan nuclear receptors: insights from structural studies
Benoit, G., Malewicz, M., & Perlmann, T. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.05.007 · Cited by 108
Steroid hormone receptors and dietary ligands: a selected review
Jacobs, M. N., & Lewis, D. F. V. (2002) · Proceedings of The Nutrition Society · doi:10.1079/pns2001140 · Cited by 100
Proline dehydrogenase (oxidase) in cancer
Liu, W., & Phang, J. M. (2012) · BioFactors · doi:10.1002/biof.1036 · Cited by 88
“PPARc belongs to the nuclear hormone receptor superfamily and functions as a ligand-dependent transcription factor [30].”
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity
Zollner, G., Wagner, M., & Trauner, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.005 · Cited by 96
“PPARs heterodimerize with RXR and bind to DR1 response elements upon activation (Willson et al., 2000; Brown & Plutzky, 2007).”
BackgroundAstarita, G., Di Giacomo, B., Gaetani, S., Oveisi, F., Compton, T. R., Rivara, S., Tarzia, G., Mor, M., & Piomelli, D. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.105221 · Cited by 90
“Such agents may not only be useful to characterize the pharmacological properties of OEA in live animals but might also provide a starting point for the development of novel antiobesity, antihyperlipidemic, and anti-inflammatory drugs (Willson et al., 2000).”
BackgroundMooradian, A. D., Haas, M. J., & Wong, N. C. W. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0013 · Cited by 91
“Some prostanoids are ligands of PPAR receptors (101, 102), and PPARs are implicated in the regulation of apo A-I expression (103, 104).”
BackgroundDong, Q., Ginsberg, H. N., & Erlanger, B. F. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00158.x · Cited by 91
Peroxisome Proliferators and Peroxisome Proliferator-Activated Receptor α
Reddy, J. K. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63787-x · Cited by 105
Zhao, X., Ou, Z., Grotta, J. C., Waxham, M. N., & Aronowski, J. A. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.061 · Cited by 100
Wang, W., Zhao, M., Cui, L., Ren, Y., Zhang, J., Chen, J., Jia, L., Zhang, J., Yang, J., Chen, G., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01256-9 · Cited by 92
Gut-liver axis calibrates intestinal stem cell fitness
Kim, G., Chen, Z., Li, J., Luo, J., Castro-Martínez, F., Wiśniewski, J., Cui, K., Wang, Y., Sun, J., Ren, X., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.001 · Cited by 93
Tenenbaum, A., Fisman, E. Z., Motro, M., & Adler, Y. (2006) · Cardiovascular Diabetology · doi:10.1186/1475-2840-5-20 · Cited by 86
“Bezafibrate, in comparison with other fibrates, has an unique characteristic profile of action since it activates all three PPAR subtypes (alpha, gamma and delta) at comparable doses [25-27].”
Regulation of Macrophage Gene Expression by the Peroxisome Proliferator-Activated Receptor-γ
Ricote, M., Welch, J. S., & Glass, C. K. (2000) · Hormone Research in Paediatrics · doi:10.1159/000053271 · Cited by 88
The long and winding road of cardiomyocyte maturation
Maroli, G., & Braun, T. W. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa159 · Cited by 93
PPARγin Inflammatory Bowel Disease
Annese, V., Rogai, F., Settesoldi, A., & Bagnoli, S. (2012) · PPAR Research · doi:10.1155/2012/620839 · Cited by 94
“Similarly to other nuclear hormone receptors, PPARγ displays a central DNA-binding domain, a C-terminal ligand-binding domain, and two transcription-activation function motifs (AF-1 and AF-2) [49].”
BackgroundAnticancer Properties of Fenofibrate: A Repurposing Use
Lian, X., Wang, G., Zhou, H., Zheng, Z., Fu, Y., & Cai, L. (2018) · Journal of Cancer · doi:10.7150/jca.24488 · Cited by 92
“PPARs belong to a nuclear hormone receptor superfamily, whose functional domains include a DNA-binding domain (DBD) and a ligand-binding domain (LBD) [23, 24].”
BackgroundTherapeutic potential of thiazolidinediones as anticancer agents
Panigrahy, D., Shen, L. Q., Kieran, M. W., & Kaipainen, A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.12.1925 · Cited by 92
“Rosiglitazone differs structurally from troglitazone and pioglitazone and has greater PPAR-γ binding affinity [3].”
BackgroundStarkey, K., Heufelder, A., Baker, G., Joba, W., Evans, M., Davies, S., & Ludgate, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020987 · Cited by 89
Ghonem, N. S., Ananthanarayanan, M., Soroka, C. J., & Boyer, J. L. (2014) · Hepatology · doi:10.1002/hep.26894 · Cited by 87
“Fibrates are synthetic PPAR ligands used clinically for the treatment of dyslipidemia,(8) although each fibrate differs slightly in its specificity for the different PPAR subtypes.(9) PPARa is predominantly expressed in the liver and regulates the transcription of several genes involved in lipid metabolism.”
BackgroundOrphan nuclear receptors in drug discovery
Shi, Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.04.006 · Cited by 100
Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury
Collino, M., Patel, N. S. A., & Thiemermann, C. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708090924 · Cited by 86
“…available TZDs, rosiglitazone and pioglitazone, were approved in the United States in 1999 and are currently used alone or in combination with other oral anti-diabetic agents for type-2 diabetes patients (Willson et al, 2000; Theocharis et al., 2003; Theocharis et al., 2004; Margeli et al, 2003).”
InfluentialReka, A. K., Goswami, M. T., Krishnapuram, R., Standiford, T. J., & Keshamouni, V. G. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.019 · Cited by 91
“The cyclopentone prostaglandin J2, was suggested to be the most potent endogenous ligand for the PPAR-γ receptor and is the most commonly used naturally occurring PPAR-γ agonist [15,16].”
BackgroundErtiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms
Erbe, D. V., Wang, S., Zhang, Y., Harding, K., Kung, L., Tam, M., Stolz, L. E., Xing, Y., Furey, S., Qadri, A., et al. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.005553 · Cited by 87
“common PPAR response element (Willson et al., 2000) were inserted”
BackgroundMethodInfluentialYamamoto, K., Itoh, T., Abe, D., Shimizu, M., Kanda, T., Koyama, T., Nishikawa, M., Tamai, T., Ooizumi, H., & Yamada, S. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.11.053 · Cited by 91
Plutzky, J. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0067-3 · Cited by 89
Eugenol and Its Role in Chronic Diseases
Fujisawa, S., & Murakami, Y. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-41342-6_3 · Cited by 86
The impact of PPARα activation on whole genome gene expression in human precision cut liver slices
Janssen, A. W. F., Betzel, B., Stoopen, G., Berends, F. J., Janssen, I. M., Peijnenburg, A. A., & Kersten, S. (2015) · BMC Genomics · doi:10.1186/s12864-015-1969-3 · Cited by 84
“This concentration was chosen based on the affinity of human PPARα for Wy14643 [32].”
BackgroundSmall molecules from natural sources, targeting signaling pathways in diabetes
Liu, Q., Chen, L., Hu, L., Guo, Y., & Shen, X. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.06.004 · Cited by 98
Brusotti, G., Montanari, R., Capelli, D., Cattaneo, G., Laghezza, A., Tortorella, P., Loiodice, F., Peiretti, F., Bonardo, B., Paiardini, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05666-6 · Cited by 87
PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
Colapietro, F., Gershwin, M. E., & Lleo, A. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100188 · Cited by 75
“Bezafibrate Different from other fibrates which are specific PPARα ligands, BZF is a weak pan-PPAR activator [31,32]; it enhances biliary excretion of PC by increasing MDR3 expression, thus play a crucial role in detoxification.”
BackgroundThe Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer
Higgins, L. S., & Mantzoros, C. S. (2008) · PPAR Research · doi:10.1155/2008/936906 · Cited by 85
“INT131 binds to PPARγ and displaces rosiglitazone with a Ki of ∼10 nM [17], demonstrating ∼20-fold higher affinity than either rosiglitazone or pioglitazone [18], and with greater than 1000-fold selectivity for PPARγ over PPARα, PPARδ, or a set of other nuclear receptors [17].”
BackgroundJones, G., Jones, D., Teal, P. E. A., Sapa, A., & Woźniak, M. (2006) · FEBS Journal · doi:10.1111/j.1742-4658.2006.05498.x · Cited by 85
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients
Tenenbaum, A., Motro, M., Fisman, E. Z., Adler, Y., Shemesh, J., Tanne, D., Leor, J., Boyko, V., Schwammenthal, E., & Behar, S. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi310 · Cited by 85
“Moreover, bezafibrate activates all three PPAR subtypes (alpha, gamma, and delta) at comparable doses.(46,47) Therefore, bezafibrate has the potential to directly improve insulin sensitization via PPAR-gamma activation.”
BackgroundYamazaki, Y., Abe, K., Toma, T., Nishikawa, M., Ozawa, H., Okuda, A., Araki, T., Oda, S., Inoue, K., Shibuya, K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.066 · Cited by 84
Skogsberg, J., McMahon, A. D., Karpe, F., Hamsten, A., Packard, C. J., Ehrenborg, E., & Study, O. B. O. T. W. O. S. C. P. (2003) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2003.01236.x · Cited by 84
Ahmed, W., Orasanu, G., Nehra, V., Asatryan, L., Rader, D. J., Ziouzenkova, O., & Plutzky, J. (2006) · Circulation Research · doi:10.1161/01.res.0000205846.46812.be · Cited by 84
Nonhuman Primates and other Animal Models in Diabetes Research
Harwood, H. J., Listrani, P., & Wagner, J. D. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600304 · Cited by 82
Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells.
Cutler, N. S., Graves‐Deal, R., LaFleur, B., Gao, Z., Boman, B. M., Whitehead, R. H., Terry, E. S., Morrow, J. D., & Coffey, R. J. (2003) · PubMed · Cited by 98
Pershadsingh, H. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.215 · Cited by 84
“The molecular mechanisms of PPAR activation and its integration with gene transcription have been reviewed [2-4].”
BackgroundAprile, M., Ambrosio, M. R., D’Esposito, V., Bèguinot, F., Formisano, P., Costa, V., & Ciccodicola, A. (2014) · PPAR Research · doi:10.1155/2014/537865 · Cited by 98
Fyffe, S. A., Alphey, M. S., Buetow, L., Smith, T. K., Ferguson, M. A. J., Sørensen, M. D., Björkling, F., & Hunter, W. N. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.12.047 · Cited by 94
Ong, K. L., Rye, K.-A., O'Connell, R., Jenkins, A. J., Brown, C., Xu, A., Sullivan, D. R., Barter, P. J., Keech, A. C., & on behalf of the FIELD study investigators (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2267 · Cited by 82
Lu, C., & Cheng, S.-Y. (2009) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0107 · Cited by 83
“1997) Clofibrate, fenofibrate, bezafibrate, gemfibrozil, ciprofibrate, Wy14 643 (Willson et al. 2000), BMS-687453, BMS-711939 (Mukherjee et al.”
Remick, J., Weintraub, H., Setton, R., Offenbacher, J., Fisher, E., & Schwartzbard, A. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e31816b43d3 · Cited by 83
“Although it is yet unknown what the interaction between those with the metabolic syndrome and fibrates is, there certainly seems to be benefits; this particular effect of preventing the onset of diabetes may be a result of bezafibrate’s unique characteristic as a pan-agonist for all 3 PPAR isoforms ( , , and ).(53,54)…”
BackgroundGeorge, J., & Liddle, C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp700110z · Cited by 81
Fenofibrate treatment in patients with primary biliary cirrhosis
Ohira, H., Sato, Y., Ueno, T., & Sata, M. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05944.x · Cited by 82
“Although there have been no epidemiological studies that prove whether or not nonsteroidal anti-inflammatory drugs reduce the incidence of gallbladder carcinoma, previous studies have demonstrated that the specific COX-2 inhibitor, but not the COX-1 inhibitor, decreased mitogenesis and increased apoptosis in cultured…”
BackgroundEdvardsson, U., von Löwenhielm, H. B., Panfilov, O., Nyström, A., Nilsson, F. Y., & Dahllöf, B. (2003) · PROTEOMICS · doi:10.1002/pmic.200390061 · Cited by 82
Metadata
- Authors
- Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R.
- Affiliations
- Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-02-01
- Volume
- 43
- Issue
- 4
- Pages
- 527-550
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1977666051
- Cited by
- 1,816
- References
- 216
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 27 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 44 · 2016: 37 · 2015: 60 · 2014: 62 · 2013: 52 · 2012: 92
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- peroxisome proliferator-activated receptors, orphan receptors, drug discovery, receptor agonists, ligands, lipid signaling, nuclear receptors
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hyperlipidemias, Hypertension, Inflammation, Ligands, Models, Molecular, Neoplasms, Nuclear Proteins, Obesity, Transcription Factors, Drug Design, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.